Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb,

 Stock Price Movement, Grants for Projects, and Clinical Data Presentations -
 Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Bristol-Myers Squibb Co. (NYSE: BMY), HCA
Holdings Inc. (NYSE: HCA), Allergan, Inc. (NYSE: AGN), and Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Gilead Sciences, Inc. Research Report

On November 15, 2013, Gilead Sciences Inc.'s (Gilead) stock rose 1.32%, ending
the day at $69.89. Over the previous three trading sessions, shares of Gilead
gained 3.37% compared to the Nasdaq Composite which gained 1.68% during the
same period. The Full Research Report on Gilead Sciences, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

Bristol-Myers Squibb Co. Research Report

On November 14, 2013, The Bristol Myers Squibb Foundation, the philanthropic
arm of Bristol-Myers Squibb Co. (Bristol-Myers Squibb), marked World Diabetes
Day and the third anniversary of its Together on Diabetes initiative by
awarding four three-year, $450,000 grants for the following projects in the
United States: Health Choice Network of Florida for the integration of
behavioral sciences and care navigation into diabetes care of high-risk
patients diagnosed with diabetes and depression; The University of Michigan
for the evaluation and comparison of the effectiveness of diabetes
self-management and psychosocial support offered at African American churches
in Detroit through either a parish peer leader or a parish nurse against those
approaches confined to diabetes self-management education alone; The
University of Colorado for the development and implementation of a program to
enhance the ability of Federally Qualified Health Centers and primary care
practices in the Denver area to provide coordinated, patient-centered care for
patients with diabetes and additional mental and behavioral health needs
through both clinic- and community-based services; and East Carolina
University for the design and evaluation of a collaborative, stepped care and
"treat to target" intervention for patients in rural eastern North Carolina
who have both uncontrolled type 2 diabetes and comorbid distress and/or
depression. The Full Research Report on Bristol-Myers Squibb Co. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

--

HCA Holdings Inc. Research Report

On November 12, 2013, HCA Holdings Inc. (HCA) announced the appointment of
Robert F. Carrel as President of HCA's Richmond, Virginia-based Capital
Division, effective January 1, 2014. The Company informed that Carrel, who has
been serving as Chief Financial Officer of the Capital Division since 2006,
will succeed Margaret Lewis, who will be retiring. According to the Company,
Carrel will have responsibility for 17 hospitals in Virginia, New Hampshire,
Kentucky, and Indiana as Capital Division President. Further, HCA informed
that it is conducting a search for a new Capital Division Chief Financial
Officer. The Full Research Report on HCA Holdings Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/be59_HCA

--

Allergan, Inc. Research Report

On November 15, 2013, Allergan, Inc.'s (Allergan) stock rose 1.05%, ending the
day at $96.41. Over the previous three trading sessions, shares of Allergan
rose 5.14%, compared to the S&P 500 which gained 1.72% during the same period.
The Full Research Report on Allergan, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/182a_AGN

--

Alexion Pharmaceuticals, Inc. Research Report

On November 9, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that
researchers presented data from four clinical trials, at Kidney Week 2013, the
annual meeting of the American Society of Nephrology (ASN) in Atlanta, all
demonstrating the clinical benefits of Soliris (eculizumab) for the treatment
of atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare
disease associated with vital organ failure and premature death. According to
Alexion, in two large, prospective, multinational studies, Soliris inhibited
systemic complement-mediated thrombotic microangiopathy (TMA, the formation of
blood clots in small blood vessels throughout the body) and improved renal
function in both pediatric and adult patients with aHUS. Further, Alexion
informed that the ASN meeting featured the presentation of three-year update
data from two pivotal Phase 2 extension studies, which highlighted the
long-term benefits of Soliris therapy in patients with aHUS. Alexion informed
that in these studies, ongoing Soliris treatment at the three-year update was
associated with sustained inhibition of complement-mediated TMA, as indicated
by stabilization or continued improvement in key hematologic and renal
endpoints, and quality of life. The Full Research Report on Alexion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4619_ALXN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.